Blog

The successful IPOs of Hinge Health, Omada Health, and HeartFlow in 2025 can be attributed to several key factors that distinguish them from the digital health companies that struggled in previous years, particularly during the "SPAC mania" of 2021. These companies demonstrated a combination of maturity, strong business fundamentals, and a clear path to value creation, making them attractive to a more discerning public market.Here's a breakdown of the reasons for their success:1. Strong Financials and a Path to ProfitabilityHinge Health: The company was already profitable on a free cash flow basis and reported a significant improvement in its net income. It was not going public out of a need for cash, which signals financial stability.Hinge Health's first quarterly results as a public company exceeded analyst expectations, showing strong revenue growth and a high operating margin.Omada Health: While not yet profitable, Omada demonstrated a clear and plausible path to profitability, with a significant narrowing of its net loss. Its first quarterly report as a public company showed strong revenue growth and improved gross margins, reassuring investors of its financial discipline.HeartFlow: Although it has had significant net losses, HeartFlow's revenue growth has been substantial, driven by its success in securing reimbursement for its services. This revenue stream, combined with the company's long operating history and large market opportunity, provided investors with a clear path to future profitability.2. Proven Business Models with Measurable OutcomesHinge Health: Hinge Health has a well-established business model centered on providing virtual musculoskeletal (MSK) care to employers and health plans. It has a high client retention rate (98%) and a high patient Net Promoter Score (NPS), backed by peer-reviewed studies demonstrating significant improvements in pain and mental health for its members. The company's technology-driven approach, which automates a large portion of care, also makes it highly scalable and efficient.Omada Health: Omada has a long operating history with a multi-condition platform for chronic diseases like diabetes and hypertension. It boasts a high customer retention rate and has 29 peer-reviewed studies validating its clinical outcomes. Its focus on behavior change and its complementary approach to GLP-1 weight-loss drugs also position it as a key partner for payers and employers grappling with rising healthcare costs.HeartFlow: The company has built a defensible business around its AI-powered diagnostic platform for coronary artery disease. Its success is heavily tied to its ability to secure reimbursement from both Medicare and private payers, which has created a steady and growing revenue stream. The company's over 3,000 peer-reviewed papers demonstrating the efficacy of its products provide a strong foundation of real-world evidence.3. Leveraging Powerful Market Trends and Technology Digital Transformation: All three companies are at the forefront of the digital health revolution, which aims to provide faster, cheaper, and smarter care. They address massive, recurring-revenue categories within healthcare, such as chronic care and musculoskeletal conditions, where there is a clear and quantifiable need for better solutions.Automation and AI: These companies are using technology, particularly AI, to automate and enhance care delivery. Hinge Health, for example, has automated 95% of human clinician hours for its physical therapy programs. HeartFlow's success is a direct validation of the market's embrace of AI in medical technology. Omada is also using AI to personalize care and provide real-time guidance to its members.Addressing Healthcare Worker Shortages: The well-reported shortage of healthcare workers has created an opening for scalable, high-quality digital solutions. These companies provide an accessible and cost-effective alternative to traditional in-person care, which is a major value proposition for their clients.&nbsp;4. Market Leadership and Operational MaturityHinge Health and Omada Health: These companies are considered leaders in their respective markets (virtual MSK and chronic care management). They have been around for a long time and have the operational maturity and experienced management teams that investors are looking for.HeartFlow: Having navigated the complex process of securing FDA clearance and reimbursement for its products, HeartFlow has demonstrated a deep understanding of the healthcare landscape and a strong ability to execute.The successful IPOs of Hinge Health, Omada Health, and HeartFlow mark a "thawing" of the public market for digital health. They are not just hype-driven ventures but mature, resilient companies with proven business models, strong financials, and the ability to demonstrate a tangible impact on patient outcomes and healthcare costsHinge Health:IPO Date: May 21, 2025Exchange &amp; Ticker: NYSE, HNGE Amount Raised: $437 million, with the IPO priced at the high end of its range at $32 per share.Performance: The stock jumped in its first day of trading, opening at $39.25 (a 23% increase) and closing up 17% from its IPO price. Hinge Health's first quarterly results as a public company showed a 55% year-over-year revenue growth.&nbsp;Omada Health:IPO Date: June 6, 2025Exchange &amp; Ticker: Nasdaq, OMDAAmount Raised: $150 million, with the IPO priced at the midpoint of its range at $19 per share.Performance: Omada's stock rose in its debut, with shares closing up nearly 20% on its first day of trading. The company reported a 49% year-over-year revenue growth in its first quarter as a public company.HeartFlow:IPO Date: August 8, 2025 Exchange &amp; Ticker: Nasdaq Global Select Market, HTFLAmount Raised: $364.2 million, which was an "upsized" offering that included the underwriters' option to purchase additional shares. The IPO was priced at $19 per share.Performance: HeartFlow's stock showed strong investor enthusiasm, closing up almost 58% over its IPO price after its first two days on public markets.These IPOs are seen as a positive sign for the healthtech sector, which has seen a drought in public offerings since 2021.The successful debuts of these companies are seen as "bellwethers," indicating a cautious reopening of the public market for mature, high-growth digital health firms with proven business models.

Hinge Health, Omada Health, Heartflow: 3 highly successful HealhTech IPO's to date in 2025

Closed-loop Vagus Nerve Stimulation (VNS) represents a profound evolution within bioelectronic medicine, transitioning from static, pre-programmed therapies to adaptive, personalised interventions. This advanced approach integrates real-time physiological data with sophisticated algorithms, including artificial intelligence, to deliver precise and responsive neuromodulation. While building upon the established efficacy of traditional VNS in conditions such as drug-resistant epilepsy, treatment-resistant depression, and stroke rehabilitation, closed-loop systems are demonstrating superior outcomes and expanding into novel therapeutic domains, including spinal cord injury, inflammatory and autoimmune diseases, and cardiovascular disorders. The progression of closed-loop VNS is underpinned by significant technological advancements, notably device miniaturisation, the emergence of non-invasive transcutaneous VNS (tVNS), wireless powering solutions, and highly specific electrode designs. These innovations enhance patient comfort, reduce invasiveness, and broaden accessibility. As a cornerstone of future health technology, closed-loop VNS is instrumental in realizing precision medicine, enabling remote patient management through digital therapeutics, and fostering a paradigm shift towards highly individualized and continuous healthcare delivery.However, the path to widespread adoption is not without its challenges, encompassing technical hurdles related to signal processing and biocompatibility, the critical need for robust clinical validation and long-term efficacy data, complex regulatory pathways and economic barriers. Furthermore, the ethical implications surrounding informed consent, patient autonomy, and equitable access to these transformative technologies demand careful consideration and proactive governance. Addressing these multifaceted challenges through collaborative efforts among industry, academia, and regulatory bodies will be pivotal in unlocking the full potential of closed-loop VNS to reshape global healthcare.To read our report in full, please click here <a data-mce-href="https://www.healthcare.digital/single-post/closed-loop-vagus-nerve-stimulation-electric-medicine-and-the-future-of-healthtech" href="https://www.healthcare.digital/single-post/closed-loop-vagus-nerve-stimulation-electric-medicine-and-the-future-of-healthtech" title="https://www.healthcare.digital/single-post/closed-loop-vagus-nerve-stimulation-electric-medicine-and-the-future-of-healthtech" target="_blank" rel="noopener">https://www.healthcare.digital/single-post/closed-loop-vagus-nerve-stimulation-electric-medicine-and-the-future-of-healthtech</a>If you would like to discuss Electric Medicine &nbsp;and how Nelson Advisors can help your Healthtech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

The Dawn of Electric Medicine and Vagus Nerve Stimulation

While AI scribes are rapidly advancing and transforming healthcare documentation, it's highly unlikely they will completely replace the Electronic Health Record (EHR) system itself. Instead, they are becoming a vital and integrated component of the EHR, enhancing its functionality and usability. &nbsp;&nbsp; Here's a breakdown of why this is the likely future: &nbsp;&nbsp; How AI Scribes Enhance EHRs: &nbsp;&nbsp; Automated Documentation: AI scribes listen to clinician-patient conversations and automatically transcribe and summarize them into structured clinical notes, directly integrating with the EHR. This significantly reduces the manual data entry burden on healthcare professionals.Reduced Burnout: By automating note-taking, AI scribes free up clinicians from "pajama time" spent on documentation, allowing them to focus more on patient care and improving job satisfaction.Improved Efficiency and Time Savings: They streamline workflows, reduce documentation time (often from minutes to seconds), and allow providers to see more patients.Enhanced Accuracy: While not perfect, AI scribes can reduce manual entry errors and standardize documentation, leading to more complete and accurate medical histories.Real-time Insights and Decision Support: Advanced AI scribes can provide coding recommendations, extract relevant patient information from the EHR (like medical history, allergies, lab results) to enrich documentation, and even offer clinical decision support.Better Patient Experience: With clinicians spending less time looking at screens, they can engage more directly with patients, improving communication and the overall patient experience.Scalability and Cost-Effectiveness: AI scribes offer a scalable solution for documentation needs, potentially reducing the need for costly human scribes.Why AI Scribes Won't Fully Replace EHRs:EHRs are Comprehensive Systems: EHRs are much more than just documentation tools. They are comprehensive systems that manage a vast array of patient data, including:Medical history (diagnoses, medications, allergies, immunizations)Lab results and imaging reportsBilling and administrative informationOrder entry (prescriptions, tests)Scheduling and appointmentsPopulation health managementRegulatory compliance and security frameworksHuman Oversight Remains Crucial: While AI scribes are highly accurate, they are not infallible. They can make errors, mishear information, omit pertinent details, or even "hallucinate" information not discussed. Clinicians must still review and verify the AI-generated notes for accuracy and completeness before signing off, as they remain responsible for the patient's record.Integration, Not Replacement: The trend is towards deeper integration of AI capabilities within EHR systems. AI is being used to enhance existing EHR functions, making them more intelligent, automated, and user-friendly.Limitations of AI: Current AI models are primarily text-based and cannot fully capture nonverbal cues, complex clinical reasoning that isn't explicitly verbalized, or information from other sources like medical devices without explicit integration.In conclusion, AI scribes are a significant step forward in addressing the documentation burden in healthcare and will continue to evolve. They are becoming an indispensable part of modern healthcare, but their role is to augment and optimize the EHR, not to entirely replace it. The future will likely see increasingly seamless and intelligent EHR systems powered by AI, with AI scribes playing a central role in automating and improving the documentation process.If you would like to discuss AI Scribes or Ambient Voice Technologies and how Nelson Advisors can help your Healthtech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Will AI scribes replace the EHR?

As a HealthTech founder, you're focused on innovation, product-market fit, and patient outcomes. But when it comes time to raise capital, you'll encounter a crucial document: the term sheet. This legal document outlines the terms of a venture capital investment, and within it, you'll find provisions that govern what happens when the company is sold. Among the most important are Drag-Along and Tag-Along clauses.Understanding these clauses is vital because they can significantly impact your control over your company and your personal financial outcome. Here’s a cheat sheet to help you navigate them.What are they?Drag-Along Clause: This is a right for the majority shareholder to force the minority shareholders to sell their shares in the event of a company sale.The "Why": A potential buyer of your HealthTech company almost always wants to acquire 100% of the shares to have complete control. The drag-along clause prevents a few small shareholders from "holding out" and blocking a sale that is otherwise beneficial for the majority. It ensures a clean and efficient exit for everyone.Who benefits? Primarily the majority shareholders, which could be the VC firm (if they hold a majority stake) or a coalition of investors and founders. However, it can also benefit founders by ensuring a viable exit isn't derailed by a single dissenting shareholder. Tag-Along Clause: This is a right for the minority shareholder to join in on a sale of shares initiated by the majority shareholders.The "Why": If a majority shareholder (like a VC fund) receives a great offer to sell their stake, a tag-along right ensures that a minority shareholder (like a founder) isn't left behind with a new, potentially less desirable, majority owner. It gives the minority the option to "tag along" and sell their shares on the same terms.Who benefits? This is a key protection for minority shareholders, including founders who may no longer hold a majority stake after several funding rounds.Special Considerations for HealthTech FoundersMission-Driven Exits: As a HealthTech founder, you may be deeply committed to the long-term mission of your company. A drag-along clause could force a sale to a buyer that doesn't align with your vision for patient care or product development. Negotiating a founder-friendly trigger threshold is crucial to maintaining some control over your company's destiny. Regulatory &amp; IP Hurdles: The value of a HealthTech company is often tied to its intellectual property (IP) and regulatory approvals (e.g., FDA, CE Mark). Ensure that the drag-along clause's terms don't put you in a position where you're forced to sell before key regulatory milestones are met, which could significantly undervalue your company. The "Liquidation Preference" Trap: VCs often have a "liquidation preference," which means they get their money back first in a sale, before common shareholders (like you). If a drag-along is triggered at a low valuation, the sale proceeds might only be enough to cover the VC's preference, leaving you with nothing. Understanding how this clause interacts with liquidation preferences is absolutely critical for your personal financial outcome. &nbsp; &nbsp;Founder's MindsetThink of these clauses as two sides of the same coin:Drag-along is for the majority's protection, ensuring they can achieve a clean exit. Tag-along is for the minority's protection, ensuring they aren't left behind. As a founder, your goal is to make sure these clauses are drafted with your interests in mind. Never assume that the "standard" terms are fair. Take the time to understand them, consult with legal counsel, and negotiate for terms that protect your vision and your equity.To discuss any of these points and how Nelson Advisors can help your Healthtech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Understanding Drag and Tag clauses for Venture Capitalists: A Cheat Sheet for HealthTech Founders

Canada, South Africa, Australia, and New Zealand are all experiencing significant activity in this sector. Each country's approach is shaped by its unique healthcare landscape, government policies, and market dynamics. Common themes include a focus on digital health, AI, and telehealth, with a mix of mergers, acquisitions, and strategic partnerships driving growth.Canada 🇨🇦Canada's HealthTech sector has seen a mix of challenges and opportunities. While venture funding has dropped in recent years, there's been an increase in M&amp;A activity.M&amp;A and Investments:Companies like Healwell AI are actively pursuing an acquisition strategy to expand their offerings. They have acquired companies focused on health data platforms and contract research to grow their business.There's a trend of private equity and venture capital firms investing in HealthTech companies. Some publicly traded Canadian HealthTech companies have gone private to restructure their strategies.Key Drivers:The market is favoring solutions that offer a clear return on investment (ROI) and can seamlessly integrate with existing systems.There is a focus on innovative medical technologies, with some firms securing large funding rounds after positive clinical trial data. South Africa 🇿🇦South Africa is a key market for HealthTech in Africa, attracting investment and partnerships aimed at addressing significant healthcare challenges.Partnerships and Investments:There's a strong emphasis on public-private partnerships and collaborations with international organizations.Initiatives like HealthTech Hub Africa are working to drive the development of health technologies and fast-track innovations into public health systems.Corporate venture capital and private equity are increasingly active, with multinational corporations partnering with local startups.The Founders Factory Africa has partnered with leading South African healthcare provider Netcare to build and scale HealthTech startups. Key Drivers:The need to bridge a significant healthcare financing gap and improve access to care, especially in rural areas, is a major motivator. Mobile technology adoption and increasing urbanization are creating new opportunities for digital health solutions. A well-established regulatory and investment ecosystem makes South Africa a leading market for medical device and biotech development on the continent. Australia and New Zealand 🇦🇺🇳🇿Australia and New Zealand, often viewed as a combined market for HealthTech, are seeing growth through both local and international investment.M&amp;A and Investments:International companies are acquiring local firms to expand their presence. For example, a UK-based tech company, System C, acquired Australian firm MYP Technologies to grow its offerings in the region.There has been an acquisition of a Victorian telehealth startup, Telecare, by a US multinational, showing the appeal of Australian innovation to global players.Venture capital activity is present, with funds closing in at significant amounts to support the sector.Key Drivers:Australia's aging population and rising chronic disease prevalence are driving demand for innovative, patient-centric care models.New Zealand has a strong heritage in HealthTech innovation, with a growing ecosystem of companies, and its export revenue is a significant indicator of the quality of its technology.Both countries are focused on leveraging technology to improve patient outcomes and address workforce challenges.Support from government agencies and various incubators and accelerators is crucial for nurturing early-stage companies and helping them scale.To discuss any of these points and how Nelson Advisors can help your Healthtech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Commonwealth Growth Strategy in HealthTech: Canada, South Africa, Australia, New Zealand

As a founder in the HealthTech space, securing venture capital (VC) funding is a critical milestone. However, the term sheets you receive often contain complex clauses that can have a significant impact on your company's future ownership structure. Among the most crucial of these are anti-dilution provisions. This cheat sheet is designed to help HealthTech founders understand what anti-dilution protection is, why VCs use it, and the different types they might encounter.What is Anti-Dilution Protection?In simple terms, anti-dilution protection is a contractual right given to investors that protects them from the dilution of their ownership stake in a company due to a future funding round at a lower valuation. This lower valuation round is often called a "down round."Imagine your HealthTech startup, "Medi-Innovate," raises a Series A round at a $20 million post-money valuation. A VC firm invests $5 million for a 25% stake. If, in a later Series B round, the company's valuation drops to $10 million, the VC's original investment would be worth less, and their percentage ownership would be diluted if new investors come in at the lower price. Anti-dilution clauses are designed to prevent this by adjusting the conversion price of the VC's preferred stock, effectively giving them more shares to maintain their original ownership percentage or value.Why Do VCs Insist on Anti-Dilution?VCs are primarily concerned with two things: return on investment and risk mitigation. Anti-dilution clauses serve both purposes:Protecting Investment Value: In a down round, the value of the VC's investment would decrease. Anti-dilution clauses ensure their stake maintains its value relative to the new, lower valuation.Mitigating Risk: They act as a form of insurance against the company underperforming or facing a difficult market, which would necessitate a down round. This is particularly relevant in the HealthTech sector, which can be sensitive to regulatory changes, clinical trial outcomes, and market shifts.Types of Anti-Dilution ProtectionThere are three primary types of anti-dilution protection you will likely encounter. They vary in severity and are a key point of negotiation.&nbsp;1. Full Ratchet Anti-Dilution (Most Favourable to VCs)How it works: This is the most aggressive form of protection. If a down round occurs, the conversion price of the investor's preferred stock is reduced to the new, lower price per share. It's as if they invested at the lowest price of the down round, regardless of the original price.&nbsp; Impact on founders: This is the most dilutive type of provision for founders and employees. The investor gets a massive increase in their share count, significantly reducing the ownership percentages of all other shareholders.&nbsp; Example: A VC invests $5 million for 1 million shares at $5/share. In a down round, new shares are sold for $2/share. With a full ratchet, the VC's shares are now converted as if they originally paid $2/share. Their original $5 million investment now converts into 2.5 million shares ($5M / $2), significantly increasing their ownership percentage and diluting the founders and other shareholders.2. Broad-Based Weighted Average (Most Common &amp; Fair)How it works: This is the most common and generally more equitable method. It calculates a new weighted average price for the investor's shares, taking into account both the original investment and the new shares sold in the down round. This calculation dilutes the VC's shares, but to a lesser degree than a full ratchet.&nbsp; &nbsp; Impact on founders: This is a much more founder-friendly approach. While it still results in some dilution, it is proportional to the number of new shares issued and the severity of the down round, rather than being a wholesale repricing of the original investment.Formula: The formula can be complex, but the key variables are:New Conversion Price = Original Conversion Price * ((Original Shares + New Shares) / (Original Shares + New Shares at New Price)) New Shares at New Price is the number of shares that would have been issued if the new price was applied to the original investment.3. Narrow-Based Weighted Average (Less Common)How it works: Similar to the broad-based method, but the calculation is more limited. It only considers the shares sold in the down round, not all outstanding shares. This results in a slightly more aggressive adjustment than broad-based but is still less severe than a full ratchet.&nbsp;Negotiating Anti-Dilution Protection As a HealthTech founder, it is crucial to negotiate these clauses. Here are some key points to consider:Aim for Broad-Based Weighted Average: This is the industry standard and a much fairer compromise. A full ratchet provision should be a major red flag, as it can be incredibly punitive.Understand the Cap on Conversion: Some agreements may cap the total number of shares an investor can receive from the anti-dilution clause, which can protect you from extreme dilution.Exemptions: Negotiate for exemptions to the anti-dilution clause. Common exemptions include:i) Shares issued for employee stock option plans (ESOPs).ii) Shares issued in a stock split or dividendsiii) Shares issued in connection with a merger or acquisition. Get Legal Counsel: Do not sign a term sheet without a lawyer specializing in venture capital. They can help you understand the long-term implications of these clauses and negotiate on your behalf. Example Scenario: The Impact Let's revisit our "Medi-Innovate" HealthTech startup.Series A: VC invests $5M for 25% of the company at a $20M post-money valuation. Share price = $5. The VC receives 1,000,000 shares. Series B Down Round: Due to a delayed FDA approval, the company raises $2M at a $10M post-money valuation. New share price = $2.ConclusionAnti-dilution clauses are a standard part of venture capital funding. While they may seem intimidating, understanding their mechanics and negotiating for the most equitable option—the broad-based weighted average—is essential for protecting your and your team's equity. By preparing and seeking expert legal advice, you can navigate these complex negotiations and ensure your HealthTech venture is on a solid foundation for future growth.To discuss any of these points and how Nelson Advisors can help your Healthtech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

Hinge Health, Omada Health, Heartflow: 3 highly successfu...

The Dawn of Electric Medicine and Vagus Nerve Stimulation

Will AI scribes replace the EHR?

Understanding Drag and Tag clauses for Venture Capitalist...

Commonwealth Growth Strategy in HealthTech: Canada, South...

Understanding anti dilution protection clauses for Ventur...